Home › Research › Drug development
Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease
Kim HY, Kim Y.. Accounts of chemical research, 2024-11-04
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
A century ago, German neurologist Alois Alzheimer documented the first case of Alzheimer's disease (AD), illuminating cognitive impairments associated with the presence of abnormal protein clusters, including amyloid plaques and tau tangles, within the brain. In a typical physiological state, the equilibrium of amyloid-β (Aβ) levels is maintained, but aging can precipitate disruptions in the homeostasis of Aβ due to its overproduction, impaired clearance, and other factors, ultimately leading to its accumulation. Although the link between Aβ aggregates and neurodegeneration has long made Aβ a promising target for AD, decades without successful drug development targeting Aβ have generated skepticism regarding the efficacy of this strategy for AD therapy.
What this study adds
Evidence grade: Low
This paper notes that decades without successful drug development targeting amyloid-β have generated skepticism about whether clearing amyloid is an effective treatment strategy. It discusses chemical-driven amyloid clearance as a possible approach for therapy and diagnosis.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kim, H. Y., & Kim, Y. (2024). Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease. Accounts of chemical research. https://doi.org/10.1021/acs.accounts.4c00458
Vancouver
Kim HY, Kim Y. Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease. Accounts of chemical research. 2024. doi:10.1021/acs.accounts.4c00458. PMID: 39496112.
BibTeX
@article{kim2024-39496112,
author = {Kim, H. Y. and Kim, Y.},
title = {{Chemical-Driven Amyloid Clearance for Therapeutics and Diagnostics of Alzheimer's Disease}},
journal = {Accounts of chemical research},
year = {2024},
doi = {10.1021/acs.accounts.4c00458},
pmid = {39496112},
url = {https://doi.org/10.1021/acs.accounts.4c00458}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In a typical physiological state, the equilibrium of amyloid-β (Aβ) levels is maintained, but aging can precipitate disruptions in the homeostasis of Aβ due to its overproduction, impaired clearance, and other factors, ultimately leading to its accumulation.
- Although the link between Aβ aggregates and neurodegeneration has long made Aβ a promising target for AD, decades without successful drug development targeting Aβ have generated skepticism regarding the efficacy of this strategy for AD therapy.
- However, recent approvals of anti-Aβ antibody drugs by the FDA, including aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla), have prompted a re-evaluation of this perspective.
- These therapies have demonstrated efficacy in reducing brain Aβ levels, thereby decelerating disease progression and reaffirming Aβ as a key target.
Why it matters
This paper notes that decades without successful drug development targeting amyloid-β have generated skepticism about whether clearing amyloid is an effective treatment strategy. It discusses chemical-driven amyloid clearance as a possible approach for therapy and diagnosis.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Accounts of chemical research) |
| Journal's citation record | 4 / 4 | Accounts of Chemical Research: journal h-index 562 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.2 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 3.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Young Soo Kim: h-index 64 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Yonsei University: institution h-index 777 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39496112) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Drug development from nearby years
Also in Drug development
124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.